Theriva Biologics Files 8-K: Material Agreement & Financials
Ticker: TOVX · Form: 8-K · Filed: May 2, 2024 · CIK: 894158
| Field | Detail |
|---|---|
| Company | Theriva Biologics, Inc. (TOVX) |
| Form Type | 8-K |
| Filed Date | May 2, 2024 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-agreement, financials, corporate-action
TL;DR
Theriva Biologics (formerly Synthetic Biologics) filed an 8-K on May 2, 2024, reporting a material definitive agreement and financial statements.
AI Summary
On May 2, 2024, Theriva Biologics, Inc. (formerly Synthetic Biologics, Inc.) filed an 8-K report. The filing indicates an entry into a material definitive agreement and includes financial statements and exhibits. The company, incorporated in Nevada, operates in the Pharmaceutical Preparations sector.
Why It Matters
This filing signals a significant development for Theriva Biologics, potentially involving a new contract or partnership, and provides updated financial information to investors.
Risk Assessment
Risk Level: medium — The filing indicates a material definitive agreement, which could represent a significant opportunity or risk depending on its terms.
Key Numbers
- 001-12584 — SEC File Number (Identifies the company's filing with the SEC.)
- 13-3808303 — IRS Employer Identification No. (Company's tax identification number.)
Key Players & Entities
- Theriva Biologics, Inc. (company) — Registrant
- Synthetic Biologics, Inc. (company) — Former company name
- May 2, 2024 (date) — Date of earliest event reported
- Nevada (jurisdiction) — State of incorporation
- 2834 (industry_code) — Standard Industrial Classification (Pharmaceutical Preparations)
FAQ
What is the nature of the material definitive agreement entered into by Theriva Biologics?
The filing does not specify the details of the material definitive agreement, only that one has been entered into.
When was the 8-K report filed?
The 8-K report was filed on May 2, 2024.
What was Theriva Biologics' former name?
Theriva Biologics, Inc. was formerly known as Synthetic Biologics, Inc.
In which state is Theriva Biologics incorporated?
Theriva Biologics, Inc. is incorporated in Nevada.
What is Theriva Biologics' Standard Industrial Classification code?
Theriva Biologics, Inc.'s Standard Industrial Classification code is 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 782 words · 3 min read · ~3 pages · Grade level 8.2 · Accepted 2024-05-02 11:59:37
Key Financial Figures
- $0.001 — ch registered Common stock, par value $0.001 per share TOVX NYSE American Indica
Filing Documents
- tm2413223d1_8k.htm (8-K) — 30KB
- tm2413223d1_ex10-3.htm (EX-10.3) — 15KB
- 0001104659-24-056146.txt ( ) — 219KB
- syn-20240502.xsd (EX-101.SCH) — 3KB
- syn-20240502_lab.xml (EX-101.LAB) — 33KB
- syn-20240502_pre.xml (EX-101.PRE) — 22KB
- tm2413223d1_8k_htm.xml (XML) — 4KB
01
Item 1.01. Entry into a Material Definitive Agreement. On May 2, 2024, Theriva Biologics, Inc. (the "Company") and A.G.P./Alliance Global Partners entered into Amendment No. 2 ("Amendment No. 2") to that certain Amended and Restated Sales Agreement dated as of February 9, 2021, as amended by Amendment No. 1 thereto dated May 3, 2021 (the "Sales Agreement"), pursuant to which the Company may offer and sell, from time to time, at its option, shares of the Company's common stock, par value $0.001 per share (the "Common Stock"), through A.G.P./Alliance Global Partners, as sales agent, in an "at the market offering" as defined in Rule 415(a)(4) under the Securities Act of 1933, as amended (the "Securities Act"). Sales in the "at the market offering" may occur under the Company's current effective registration statement on Form S-3 (File No. 333-255726) utilizing a prior prospectus and related prospectus supplements thereto or a newly filed registration statement on Form S-3 once it has been declared effective under the Securities Act. The description of the Sales Agreement, including Amendment No. 1 thereto and Amendment No. 2 does not purport to be complete and is qualified in its entirety by reference to the full text of the Sales Agreement, Amendment No. 1 and Amendment No. 2, copies of which are included herewith as Exhibits 10.1. 10.2 and 10.3, and are incorporated herein by reference. In addition, on May 1, 2024, the Company and B. Riley Securities, Inc. mutually agreed to enter into into a notice of termination whereby B. Riley Securities, Inc. would no longer be a party to the Sales Agreement.
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits. Exhibit Number Description 10.1 Amended and Restated At Market Issuance Sales Agreement, dated February 9, 2021, by and among Synthetic Biologics, Inc., B. Riley Securities, Inc. and A.G.P./Alliance Global Partners (Incorporated by reference to Exhibit 1.1 of the Registrant's Current Report on Form 8-K filed February 9, 2021, File No. 001-12584.) 10.2 Amendment No. 1 to the Amended and Restated At Market Issuance Sales Agreement, dated May 3, 2021, by and among Synthetic Biologics, Inc., B. Riley Securities, Inc. and A.G.P./Alliance Global Partners (Incorporated by reference to Exhibit 1.2 of the Registrant's Current Report on Form 8-K filed May 3, 2021, File No. 001-12584.) 10.3 Amendment No. 2 to the Amended and Restated At Market Issuance Sales Agreement, dated May 2, 2024 by and between Theriva Bilogics, Inc. and and A.G.P./Alliance Global Partners 104 Cover Page Interactive Data File (embedded within the XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: May 2, 2024 THERIVA BIOLOGICS, INC. By: /s/ Steven A. Shallcross Name: Steven A. Shallcross Title: Chief Executive Officer and Chief Financial Officer